A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is application/pdf.
Performance and clinical decision-making using the prognostic 40-gene expression profile (40-GEP) test in 1,018 patients with high-risk cutaneous squamous cell carcinoma (SCC)
2022
SKIN The Journal of Cutaneous Medicine
Preserved Fulltext
This study was sponsored by Castle Biosciences, Inc. (CBI), which provided funding to the contributing centers for tissue and clinical data retrieval. JJS, AP, and MSG are employees and options holders of CBI. ASF is a consultant for CBI. 40-GEP Risk Class Overall Cohort 3-year MFS (95% CI) Overall Event Rate Univariate Cox regression analysis (HR) Class 1 95.3% (93.6-97.0%) 5.1% 1 Class 2A 81.9% (78.2-85.8%) 18.8% 4.0 Class 2B 56.9% (44.8-72.2%) 43.1% 11.4 Without 40-GEP 88.2% (86.3-90.2%) 12.3% --Methods
doi:10.25251/skin.6.supp.96
fatcat:etrkvmu3ezc2toau3imtbklv7u